⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Gossamer Bio and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Gossamer Bio
↗San Diego, United States
Gossamer Bio, Inc. is a San Diego-based clinical-stage biopharmaceutical company focused primarily on seralutinib, an investigational inhaled small-molecule inhibitor of PDGFR-alpha/beta, CSF1R, and c-KIT. The company is developing seralutinib for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), with a strategy centered on pulmonary hypertension and rare-disease drug development. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000017/goss-20251231.htm))
Gossamer was incorporated in Delaware in October 2015 under the name FSG Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company went public on Nasdaq in February 2019. In 2026, it became highly concentrated around seralutinib after its Phase 3 PROSERA study narrowly missed its prespecified statistical threshold, its PH-ILD Phase 3 SERANATA study was suspended, and the company implemented cost reductions. Following a June 2026 FDA pre-NDA meeting, Gossamer stated that it intended to submit a seralutinib NDA for PAH in September 2026. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000017/goss-20251231.htm?utm_source=openai))
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:-
Industry:Biotechnology
Sub-Industry:Pulmonary hypertension and rare-disease therapeutics
SIZE & FINANCIALS
Employees:51-200
Revenue:$0M-$50M; reported $9.2M of collaboration revenue in Q2 2026 and $26.2M for the first six months of 2026. ([ir.gossamerbio.com](https://ir.gossamerbio.com/news-releases/news-release-details/gossamer-bio-announces-second-quarter-2026-financial-results-and))
Founded:2015
Ownership:public
Status:operating
FUNDING
Stage:Public / post-IPO
Total Raised:$1.0B+ in equity, debt, and other financings since inception; company management has described completing nearly $1.0 billion in financings. ([gossamerbio.com](https://www.gossamerbio.com/about/team/?utm_source=openai))
Investors:Omega Funds — founding seed investor and co-lead of the initial Series A. ([ir.gossamerbio.com](https://ir.gossamerbio.com/news-releases/news-release-details/former-receptos-executives-launch-gossamer-bio-inc-new-biopharma/?utm_source=openai)), ARCH Venture Partners — co-lead of Gossamer's initial $100 million Series A. ([ir.gossamerbio.com](https://ir.gossamerbio.com/news-releases/news-release-details/former-receptos-executives-launch-gossamer-bio-inc-new-biopharma/?utm_source=openai))
STOCK
Exchange:NASDAQ Global Select Market
Ticker:GOSS
Market Cap:$47.0M as of 2026-08-19.
PIPELINE
Stage:Phase 3 / NDA preparation
Lead Drug Stage:Seralutinib is in the post-Phase 3, pre-NDA stage for PAH; Gossamer stated that its NDA submission is planned for September 2026, with a potential FDA decision in Q3 2027 if accepted for filing. ([ir.gossamerbio.com](https://ir.gossamerbio.com/news-releases/news-release-details/gossamer-bio-announces-second-quarter-2026-financial-results-and))
Modalities:Small molecule, Inhaled therapy, Dry-powder inhaler, Oral small molecule, Combination drug-device product
Active Trials:2
Trial Phases:Phase 3: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Gossamer Bio 002, Inc. — Delaware, Gossamer Bio Services, Inc. — Delaware, Gossamer Bio Holdings, Ltd. — Ireland, Gossamer Bio 002, Ltd. — Ireland, GB001, Inc. — historical or legacy program subsidiary, GB003, Inc. — historical or legacy program subsidiary, GB004, Inc. — historical or legacy program subsidiary, GB007, Inc. — historical or legacy program subsidiary, GB008, Inc. — historical or legacy program subsidiary
Key Partnerships:Chiesi Farmaceutici S.p.A. — entered a global seralutinib development and commercialization collaboration in May 2024, originally involving a $160M development reimbursement, up to $146M in regulatory milestones, up to $180M in sales milestones, U.S. profit sharing, and ex-U.S. royalties. Gossamer terminated the collaboration and reacquired worldwide rights in July 2026. ([gossamerbio.com](https://www.gossamerbio.com/about/collaboration/?utm_source=openai)), Pulmokine, LLC — source of exclusive seralutinib licenses covering method-of-use, compound, formulation, and related intellectual property. ([ir.gossamerbio.com](https://ir.gossamerbio.com/static-files/5fa26c3e-c190-43ec-b013-153047100012?utm_source=openai)), Gilead Sciences, Inc. — co-owner with Pulmokine of certain seralutinib patent rights licensed to Gossamer. ([ir.gossamerbio.com](https://ir.gossamerbio.com/static-files/5fa26c3e-c190-43ec-b013-153047100012?utm_source=openai)), Respira Therapeutics / Samsara BioCapital — option arrangement for potential acquisition of Respira and RT234, an inhaled on-demand vardenafil program. ([ir.gossamerbio.com](https://ir.gossamerbio.com/news-releases/news-release-details/gossamer-bio-enters-option-agreement-acquire-respira/?utm_source=openai))
COMPETITION
Position:Emerging
Competitors:Merck & Co. — Winrevair/sotatercept, United Therapeutics — Tyvaso/treprostinil, Orenitram, and other pulmonary-hypertension therapies, Johnson & Johnson / Janssen — Opsumit/macitentan and Uptravi/selexipag, Bayer — Adempas/riociguat, Liquidia Technologies — Yutrepia/treprostinil and other pulmonary-hypertension products, Aerovate Therapeutics — inhaled pulmonary-arterial-hypertension development programs
LEADERSHIP
Key Executives:
Faheem Hasnain - Co-Founder, Chairman, President and Chief Executive Officer
Bryan Giraudo - Chief Operating Officer and Chief Financial Officer
Bob Smith - Chief Commercial Officer
Christian Waage - Executive Vice President and General Counsel
Caryn Peterson - Executive Vice President, Regulatory Affairs
Jean-Marie Bruey, Ph.D. - Senior Vice President, Translational Medicine and Research
Scientific Founders:Faheem Hasnain — co-founder and current CEO. ([ir.gossamerbio.com](https://ir.gossamerbio.com/news-releases/news-release-details/former-receptos-executives-launch-gossamer-bio-inc-new-biopharma/?utm_source=openai)), Sheila Gujrathi, M.D. — co-founder and former Receptos executive; announced with Hasnain at Gossamer's launch in January 2018. ([ir.gossamerbio.com](https://ir.gossamerbio.com/news-releases/news-release-details/former-receptos-executives-launch-gossamer-bio-inc-new-biopharma/?utm_source=openai))
Board Members:Faheem Hasnain — Chairman and CEO, Russell Cox — Director, Skye Drynan — Director, John Quisel, Ph.D., J.D. — Director, Thomas Daniel, M.D. — Lead Independent Director, Sandra Milligan, M.D., J.D. — Director, Steven Nathan, M.D. — Director
LINKS
Website:gossamerbio.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Gossamer Bio. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.